NK cell therapy with two immune agents for returning lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell or follicular lymphoma that came back or didn't respond to at least 2 prior treatments or a stem cell transplant.
- You either had CAR-T therapy that didn't work or you are not able to get CAR-T cells.
- Your tumor has a marker called CD19 or CD20 (a test from a biopsy).
- You are between 18 and 80 years old.
- Your kidneys, liver, lungs, and heart are working well enough (doctors will check).
- You are not pregnant or breastfeeding, and if you are able to have children, you agree to use very effective birth control during and for some time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy for people with certain types of lymphoma (Hodgkin or diffuse large B-cell) that did not respond fully to first treatment or came back within a year. The therapy uses modified natural killer (NK) cells that target a protein called CD70 found on the cancer cells.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
Hear when a new Recurrent B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.